newsfilter
← Latest News
Business Wire·

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b study Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from